1st Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$2,550,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions R&D Tax Credit Anti-Inversion Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
BRENDA J LUCKRITZ —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; State, Dept of (DOS); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID)

Budget/Appropriations BUD

Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2015 Labor HHS Appropriations Bill

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
BRENDA J LUCKRITZ —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: Commerce, Dept of (DOC); SENATE; State, Dept of (DOS); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

HR3116 MODDERN Cures Act of 2013 Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Draft Legislation on Trade Secret Issues

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
BRENDA J LUCKRITZ —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); State, Dept of (DOS); SENATE; U.S. Trade Representative (USTR)

Bills named: H.R. 3116 (114th)

Health Issues HCR

Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act Dextromethorphan - Age Restrictions - Controlling bulk shipments - PACT Act FSA/HSA - Support reinstating coverage of OTC products HR351/S351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Elibibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Medical Device Tax Repeal Drug Importation Limitations on lawful use of caffeine Reimbursement for medical devices GMP related to manufacturing sites Federal BTC and GMO labeling laws Biosimilars 21st Century Cures PDUFA 340B Drug Discount Program Low-income Subsidy in Part D

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
BRENDA J LUCKRITZ —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Bills named: H.R. 351 (114th)

Medicare/Medicaid MMM

Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
BRENDA J LUCKRITZ —
SHAWN O'NEAIL —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines Global Intellectual Property Issues Including: - Trade Promotion Authority - Trans-pacific Partnership - Trans Atlantic Trade and Investment Partnership HR3830/S1900 - Bipartisan Congressional Trade Priorities Act of 2014 International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Bills named: H.R. 3830 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.